References
- Sundhedsstyrelsen. Arvelig nonpolypøs tyk- og endetarmskræft i Danmark – en medicinsk teknologivurdering. Sst 2007;7.
- Vasen HFA, Möslein G, Alonso A, Bernstein I, Bertario L, Blanco J, Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J MedGenet 2007;44:353–62.
- Gylling AH, Nieminen TT, Abdel-Rahman WM, Nuorva K, Juhola M, Juensoo EL, Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 2008;29:1351–9.
- Rouptrêt M, Yates DR, Comperat E, Cussenot O Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 2008;54:1226–36.
- Blaszyk H, Wang L, Dietmaier W, Hofstädter F, Burgart LJ, Cheville JC, Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis. Mod Pathol 2002;15:790–7.
- Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, The risk of extra-colonic, extra-endometrial cancer in Lynch syndrome. Int J Cancer 2008;123:444–9.
- Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne LJ, Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). FamCancer 2008;7:163–72.
- Bermejo JL, Eng C, Hemminki K. Cancer characteristics in Swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer. Gastroenterology 2005;129:1889–99.
- Van der Post RS, Kiemeney LA, Ligtenberg MJ, Wintjes JA, Hulsbergen-van de Kaa CA, Bodmer D, Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSN2 mutation carriers. JMedGenet 2010;47:460–70.
- Murphy WM. What's the trouble with cytology? J Urol 2006;176:2343–6.
- Myrhøj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. FamCancer 2008;7:303–7.
- Acher P, Kiela G, Thomas K, O'Brien T. Toward a rational strategy for surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int 2010;106:300–2.